
Iben Kümler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/39431/publications.pdf Version: 2024-02-01



IREN KÃ1/MIED

#	Article	IF	CITATIONS
1	A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treatment Reviews, 2014, 40, 259-270.	7.7	141
2	A systematic review of bevacizumab efficacy in breast cancer. Cancer Treatment Reviews, 2014, 40, 960-973.	7.7	59
3	A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 138, 347-358.	2.5	54
4	Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO Open, 2016, 1, e000062.	4.5	43
5	Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development. Frontiers in Oncology, 2013, 3, 313.	2.8	42
6	PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies. Breast Cancer Research and Treatment, 2020, 181, 553-560.	2.5	29
7	Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence. ESMO Open, 2016, 1, e000093.	4.5	27
8	Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast Cancers. Cancers, 2021, 13, 3050.	3.7	21
9	Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 62-71.	1.2	20
10	Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer. Radiologia Medica, 2015, 120, 536-541.	7.7	17
11	Topoisomeraseâ€1 gene copy aberrations are frequent in patients with breast cancer. International Journal of Cancer, 2015, 137, 2000-2006.	5.1	14
12	Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. Cancer Chemotherapy and Pharmacology, 2019, 83, 169-178.	2.3	12
13	A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol. BMC Cancer, 2015, 15, 78.	2.6	9
14	Drug transporters in breast cancer: response to anthracyclines and taxanes. Expert Review of Anticancer Therapy, 2015, 15, 1075-1092.	2.4	6
15	Trials of bevacizumab in breast cancer – a safety review. Expert Opinion on Drug Safety, 2012, 11, S37-S48.	2.4	5
16	Expression Patterns of Biomarkers in Primary Tumors and Corresponding Metastases in Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 13-19.	1.2	5
17	Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. BMC Cancer, 2019, 19, 573.	2.6	4
18	An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. Cancer Chemotherapy and Pharmacology, 2019, 84, 441-446.	2.3	3

#	Article	IF	CITATIONS
19	Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial Journal of Clinical Oncology, 2014, 32, TPS1139-TPS1139.	1.6	0
20	Prediction of exemestane benefit in patients with advanced breast cancer based on diagnostic biopsy mRNA analysis Journal of Clinical Oncology, 2017, 35, e12532-e12532.	1.6	0